Clinical trials: Endothelial Corneal Dystrophy
Pseudophakic Bullous Keratopathy, Fuchs' Endothelial Dystrophy
Endothelial Side Up Inverted Femtosecond Laser Assisted DSAEK
To evaluate the clinical outcomes (pos toperative best corrected visual acuity, endothelial count) and anatomical results (interface smoothness) of DSAEK with Femto LDV-prepared grafts from the endothelial side.
- Trial name
- NCT06652321
- Testing
- Endothelial Side Up Femtosecond Laser Assisted DSAEK
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Dar El Oyoun Hospital
Corneal Edema, Corneal Endothelial Dystrophy
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.
- Conditions
- Corneal Edema, Corneal Endothelial Dystrophy, Endothelial Dysfunction, Fuchs Dystrophy
- Trial name
- NCT05636579
- Testing
- EO2002, Ripasudil
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Fuchs' Endothelial Dystrophy
A Comparison of Visual Functions and Side-effects After DSAEK or DMEK for Fuchs' Endothelial Dystrophy
Descemet's stripping automated endothelial keratoplasty (DSAEK) and Descemet's membrane endothelial keratoplasty (DMEK) are becoming increasingly popular as treatments for Fuchs' endothelial dystrophy.
- Trial name
- NCT04417959
- Testing
- Phaco-DSAEK, Phaco-DMEK
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- University of Aarhus
Corneal Endothelial Cell Loss, Fuchs' Endothelial Dystrophy
Technique And Results In Endothelial Keratoplasty
To assess and compare the complications and results of different lamellar endothelial keratoplasty techniques and its variations.
- Trial name
- TREK (NCT02470793)
- Testing
- Descemet Stripping Automated Endothelial Keratoplasty, Descemet Membrane Endothelial Keratoplasty
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- EDUARD PEDEMONTE-SARRIAS
Fuchs' Corneal Endothelial Dystrophy (FCED)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal…
- Trial name
- SPIFD-101 (NCT02653391)
- Testing
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stealth BioTherapeutics Inc.
Fuchs' Endothelial Dystrophy, Cataract
Using the Optovue OCT to Select IOL Power
Many patients with endothelial dysfunction also present with cataracts. It is therefore common practice to perform cataract extraction and intraocular lens (IOL) implantation during the same operation and immediately prior to…
- Trial name
- NCT01361282
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Legacy Health System
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Trial name
- INTREPID (NCT04520321)
- Testing
- TTHX1114(NM141)
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Trefoil Therapeutics, Inc.
Fuchs' Endothelial Dystrophy
Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy
Fuchs Endothelial Dystrophy (FED) is a degenerative disease affecting the corneal endothelium. The current gold-standard for treatment of severe FED is endothelial keratoplasty, wherein a cadaveric Descemet's membrane /…
- Trial name
- NCT03275896
- Testing
- Descemet Membrane Transplantation
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore National Eye Centre
Cystoid Macular Edema, Fuchs Dystrophy
Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
This study aims to evaluate and compare incidence of post-operative cystoid macular edema (CME) after Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet's Stripping Automated endothelial Keratoplasty (DSEK) and Descemet…
- Trial name
- NCT04527523
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Wake Forest University Health Sciences
Keratoconus, Fuchs' Endothelial Dystrophy
Long Term Cornea Graft Survival Study
Corneal transplantation have been performed for several decades, follow-up time in some centers now exceeds 30 years. Published long term (10 years and up) graft survivals vary considerably from center to center.
- Trial name
- BELIEvE (NCT02849808)
- Where
- France
- Volunteers
- 564 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Corneal Dystrophies, Hereditary
Descemet Stripping (Automated) Endothelial Keratoplasty (DSEK or DSAEK)
To evaluate the transplantation of a posterior corneal disc for the management of corneal endothelial disorders in Descemet Stripping Endothelial Keratoplasty (DSEK) or Descemet Stripping Automated Endothelial Keratoplasty…
- Trial name
- DSAEK (NCT00543660)
- Testing
- Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Netherlands Institute for Innovative Ocular Surgery
Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years
This multi-center clinical trial is designed to assess the association of diabetes in a cornea donor with transplant success and loss of endothelial cells 5 years following Descemet membrane endothelial keratoplasty (DMEK).
- Trial name
- DEKS (NCT07217249)
- Testing
- Descemet membrane endothelial keratoplasty
- Where
- 14 sites in United States
- Volunteers
- 570 people
- Sponsor
- Case Western Reserve University
Keratoconus, Fuchs' Endothelial Dystrophy
Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study
Immune rejection episodes after penetrating keratoplasty occur in 30% of patients and constitute one of the main factors reducing graft survival. They mainly occur during the first 18 months.
- Conditions
- Keratoconus, Fuchs' Endothelial Dystrophy, Congenital Hereditary Stromal Dystrophy of the Cornea
- Trial name
- IDEXACOR (NCT02834260)
- Testing
- Dexamethasone implant OZURDEX
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Retinal Diseases, Fuchs Endothelial Dystrophy
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
Optical coherence tomography (OCT )provides high resolution information regarding the anatomic structure of the tissues of the eye in a cross-sectional and 3 dimensional view.
- Conditions
- Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane
- Trial name
- DISCOVER (NCT02423213)
- Where
- United States
- Volunteers
- 2,911 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Bullous Keratopathy, Corneal Endothelial Dystrophy
Simple Non-cultured Endothelial Cell Therapy for Corneal Endothelial Dysfunction
Assessment of safety and efficacy of cell injection therapy generated using non-cultured human corneal endothelial cells in treating corneal endothelial dysfunction
- Trial name
- NCT07711561
- Testing
- Cell injection
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Singapore Eye Research Institute
Fuchs' Endothelial Dystrophy, Cataract
Risk Assessment for Progression to DMEK Following Cataract Surgery in Fuchs Endothelial Corneal Dystrophy
Justification. Fuchs' corneal endothelial dystrophy (FECD) is one of the main causes of corneal transplantation. In many cases, the corneal decompensation derived from this dystrophy is triggered as a consequence of cataract…
- Trial name
- NCT04072029
- Testing
- Phacoemulsification with intraocular lens implantation
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Corneal Dystrophies
Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France
The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy, FECD) is beginning to be dismembered.
- Trial name
- F3S2 (NCT05742321)
- Testing
- Genotyping, Histology, Collection of data
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Corneal Disease, Endothelial Corneal Dystrophy
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
The goal is to develop a nationwide registry to track longitudinal clinical outcomes of and store imaging data related to numerous corneal conditions.
- Conditions
- Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
- Trial name
- NCT06101017
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nitin Vaswani
Fuchs' Dystrophy, Corneal Edema
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Graft rejection has traditionally been one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used for an extended period after transplant surgery.
- Trial name
- NCT01853696
- Testing
- loteprednol etabonate, prednisolone acetate 1%
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Cornea Research Foundation of America
Fuchs Endothelial Corneal Dystrophy, FECD3
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide…
- Conditions
- Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases, LRS
- Trial name
- Fuchs Focus (NCT05052554)
- Testing
- QR-504a
- Where
- United Kingdom
- Sponsor
- ProQR Therapeutics